Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

Lafeuillade, Alain; Hittinger, Gilles; Chadapaud, S

doi:10.1016/s0140-6736(00)03618-7

Cited by 287 publications

(160 citation statements)

References 5 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…In anucleate cells that also lack dephosphorylation enzymes such as erythrocytes, RBV is irreversibly phosphorylated intracellularly [29]. In these cells, RBV triphosphate accumulates resulting in competitive inhibition of ATP-dependent oxidative respiration, shortened erythrocyte survival and hemolytic anemia [30,31]. We found that week 4 hemoglobin declines were significantly greater in SVRs compared with NRs.…”

Section: Discussionmentioning

confidence: 82%

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

Dahari¹,

Markatou²,

Zeremski³

et al. 2007

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 82%

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

Dahari¹,

Markatou²,

Zeremski³

et al. 2007

Journal of Hepatology

View full text Add to dashboard Cite

show abstract

“…However, psychiatric disorders are of special concern, because of their potential severity and the high rate of treatment discontinuation. No deaths, life-threatening complications such as lactic acidosis and pancreatitis, [6][7][8]16 or new or unexpected adverse events were seen. In addition, a high rate of liver decompensation in the course of treatment was reported in coinfected patients with histologically proven cirrhosis.…”

Section: Discussionmentioning

confidence: 96%

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Santín

Shaw²,

García³

et al. 2006

AIDS Research and Human Retroviruses

View full text Add to dashboard Cite

show abstract

“…Toxicity at mitochondrial level has been described with the concomitant use of Ribavirin in coinfected patients, and mainly associated with the use of nucleoside reverse transcriptase inhibitors 12 .…”

Section: Discussionmentioning

confidence: 99%

Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the antiretroviral therapy received

Navarro

Mendes-Corrêa

Cavalheiro

et al. 2005

Rev. Inst. Med. trop. S. Paulo

View full text Add to dashboard Cite

SUMMARYDuring the year of 2001, a retrospective, descriptive study in order to determine the influence of the antiretroviral therapy received by 111 HIV-HCV coinfected patients who had undergone at least one liver biopsy was conduced, 74 of them were treated with a protease inhibitor regimen (WPI), and 37 with a non-protease inhibitor regimen (NPI). The main characteristics found were: a young patient population (mean age 41 years old in both groups), composed in most part of male individuals (74.3% WPI and 51.4% NPI) with previous risk factors for both infections (WPI 93.2% and NPI 89.2%). The most significant findings included AIDS-defining disease (WPI 18.9% and NPI 13.5% of the cases), elevated hepatic enzyme levels (WPI: SGOT 52.1 and NPI 53.2), absence of liver disease-related symptoms (16.2% for both groups), average CD4 count > 350 for both groups (WPI 362.2 and NPI 378.1), predominantly low-grade fibrosis in both populations (0-2 in 63.6% of WPI patients and in 80% of NPI patients), with necro-inflammatory activity ranging from 5-7 in 51.3% and 42.9% of WPI patients and NPI patients, respectively. It is suggested a sequential biopsy to better evaluate the evolution of the hepatic disease, according to the HAART regimen received.

show abstract

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

Cited by 287 publications

References 5 publications

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin

Efficacy and Safety of Pegylated Interferon-α2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Patients

Clinical laboratory assessment of hepatitis C and HIV coinfected patients according to the antiretroviral therapy received

Contact Info

Product

Resources

About